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Abstract
Posttraumatic stress disorder (PTSD) is an anxiety disorder initiated by exposure to a traumatic
event and characterized by intrusive thoughts about the event, attempts to avoid reminders of the
event, and physiological hyperarousal. In a number of large prospective observational studies,
PTSD has been associated with incident cardiovascular disease (CVD) and mortality. Also, in
recent years, a number of studies have shown that cardiovascular events can themselves cause
PTSD in more than 1 in 8 patients with acute coronary syndrome. Further, a few small studies
suggest that PTSD secondary to an acute CVD event then places patients at increased risk for
subsequent CVD events and mortality. In this article, we review the evidence for a link between
PTSD and CVD, and discuss potential mechanisms for that association as well as future directions
for research.
Posttraumatic stress disorder is an anxiety disorder initiated by an exposure to a traumatic
event, such as combat, natural disaster, or sexual assault, and is characterized by symptoms
such as re-experiencing the traumatic event (e.g., intrusive thoughts, nightmares), cognitive
or behavioral avoidance of reminders of the event, and physiological hyperarousal. It is
associated with abnormal amygdala, prefrontal cortex, and hippocampal function 1 as well
as abnormal neuroendocrinologic characteristics. 2 Increasingly, PTSD is also being
recognized as an independent risk factor for cardiovascular disease (CVD).3–5 This paper
outlines our current understanding of the association of PTSD and CVD, and considers 2
propositions concerning the association: (1) PTSD due to traumatic life events increases risk
for incident CVD, and (2) the experience of life-threatening CVD may cause PTSD, and
increase recurrent CVD risk.
PTSD and risk for incident CVD/mortality
In recent years, evidence has accumulated that PTSD due to various types of traumatic
experiences, including exposure to combat, the World Trade Center attacks, and other
similar life-threatening events is associated with development of cardiovascular disease,
acute coronary syndromes, and cardiac-specific mortality. To date, 5 prospective cohort
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studies (with a total of 401,712 participants) have estimated the association of PTSD with
incident CVD and/or mortality.6–10 Those studies adjusted for numerous demographic,
clinical, and psychosocial factors including depression, and followed participants from 1 to
30 years. The effect sizes they reported have ranged from a hazard ratio for incident CVD
and/or cardiac mortality of 1.46 to 3.28. Given the consistent findings of these studies on
PTSD and CVD, attention has turned to understanding the pathologic mechanisms that
connect these two disorders.11
Mechanisms linking PTSD to CVD
Several studies have found the association of PTSD and CVD to be independent of
traditional CVD risk factors, such as hypertension, diabetes, and dyslipidemia.12 Therefore,
we must consider other mechanisms through which PTSD could cause CVD. Though no
studies have comprehensively evaluated the mechanisms linking PTSD and CVD, a number
of potential mechanisms have been proposed. These can be classified into three categories
that will be discussed below: biological, behavioral, and psychosocial risk factors.
Biological risk factors
Biological mechanisms of increased CVD risk in PTSD include dysregulation of the
hypothalamic-pituitary-adrenal (HPA) axis, autonomic nervous system dysfunction, and
increased inflammation. 4,13 The neurobiology of PTSD is complex, with conflicting reports
about basal as well as reactive cortisol levels in patients with PTSD.14,15 Overall, studies
indicate that the disruption of the HPA axis in patients with PTSD leads to lower basal
cortisol secretion, but exaggerated secretion in response to psychological stressors, such as
trauma reminders. HPA hyperreactivity, in turn, has been implicated in the development of
heart failure and cardiac ischemia and is prospectively associated with increased CVD
mortality. Other neuroendocrine alterations observed in PTSD include increased negative
feedback sensitivity of glucocorticoid receptors in the stress-response system, decreased
glucocorticoid responsiveness,15 and lower urinary and plasma cortisol levels. Autonomic
balance may also be altered, as evidenced by an exaggerated catecholamine response to
stressful circumstances16 and higher concentrations of circulating catecholamines.17
Alterations in these pathways may lead to CVD via increases in blood pressure and
coagulation, as elevated catecholamines have direct effects on the heart, blood vessels, and
platelets.18,19 Catecholamines have also been implicated in the development of heart failure
and cardiac ischemia.20–22 In addition, patients with PTSD demonstrate decreased heart rate
variability, baroreflex dysfunction, and increased QT variability on electrocardiograms.17
Each of these physiologic measures has been linked to CVD risk, as reduced heart rate
variability predicts mortality after myocardial infarction,23 reduced baroreflex sensitivity has
been linked with carotid atherosclerosis and increased risk of CVD,17 and increased QT
variability is a predictor of sudden cardiac death.24
Inflammation is another important potential mechanism of increased CVD risk. Though
increases in inflammatory cytokines can be adaptive in the setting of repair of acute injury,
chronic inflammation is now recognized to be a major factor in the pathogenesis and
progression of cardiovascular disease.25,26 von Känel and colleagues found a dose-response
relationship between severity of PTSD symptoms and inflammation, including increased
levels of tumor necrosis factor α and interleukin 1β and decreased levels of the anti-
inflammatory cytokine interleukin 4.27,28 Several other studies of PTSD and inflammation
have reported conflicting results, potentially due to small sample sizes and variations in
measurements. However, a recent systematic review confirmed that the majority of studies
demonstrated patients with PTSD had higher levels of inflammation.29,30 Finally, as studies
shed light on the genetics of PTSD, we may find shared variance in susceptibility to PTSD
and CVD or its risk factors.
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Potential behavioral mediators of increased CVD risk include substance use, obesity,
decreased physical activity, medication nonadherence, and sleep disturbance. Patients with
PTSD are known to have higher rates of tobacco use and alcohol and substance dependence
even when compared to trauma-exposed controls, and use and dependence may be related to
self-medication of anxiety and hyperarousal symptoms.31,32 Patients with PTSD also face
added challenges when attempting to reduce substance use. For example, in a study of
tobacco cessation, those with PTSD experienced significantly greater withdrawal symptoms
and urges to smoke after overnight abstinence.33 PTSD has also been associated with a
substantially increased risk of obesity in large epidemiologic studies as well as a national
study of administrative data from younger veterans.34,35 This association is likely
multifactorial and could involve several other lifestyle factors, such as poor diet and
decreased physical activity. Though little data has been published on dietary intake in
patients with PTSD, multiple studies, including one conducted in patients with existing
CVD, have found patients with PTSD report lower rates of physical activity.36,37 Sedentary
behavior may be particularly important as it is strongly connected to other cardiac risk
factors, such as increased blood pressure, insulin resistance, and cholesterol levels.38
Beyond these lifestyle factors, we and others have shown that PTSD is associated with
nonadherence to prescribed medications, another predictor of CVD events.39,40 Finally,
patients with PTSD experience numerous sleep disturbances, including nightmares,
difficulty falling/staying asleep, and sleep disordered breathing.41 These sleep disturbances
may result from increased release of corticotropin releasing hormone and other mediators of
anxious arousal in the brain.42 In addition to being distressing for the patient, such sleep
disturbances are now recognized as important risk factors for the development and
progression of CVD.43,44
Psychosocial risk factors
Comorbid psychological disorders and impairments in social functioning may also increase
CVD risk in patients with PTSD. Though the association between PTSD and CVD has
remained significant after adjustment for depression in several studies, depression remains a
strong risk factor for CVD and could further increase risk of cardiac events when present.45
A recent meta-analysis of 39 studies also found strong associations between PTSD and
anger and hostility.46 Higher levels of anger and hostility, in turn, are associated with
significant increases in anginal symptoms, myocardial infarction, and angiographic severity
of CVD.47
In addition to these psychological risk factors, the avoidance symptoms present in PTSD can
lead to difficulties with developing and maintaining relationships that may decrease social
networks and support. In a community-based study of 2,985 adults, those with PTSD
reported significantly lower levels of social support and greater social phobia.48 Social
isolation has been linked to decreased survival following myocardial infarction and to higher
total morality.49 Lastly, PTSD is associated with emotional and physical disabilities that can
decrease socioeconomic status. In the National Comorbidity Survey, a population-based
study of U.S. adults, participants with PTSD had a 40% increased likelihood of not
completing high school or college and a 150% increased likelihood of current
unemployment compared to participants without PTSD. Socioeconomic status is strongly
associated with an increased risk of CVD events and mortality independent of traditional
CVD risk factors and access to healthcare. 50
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Possible interventions to reduce CVD risk
Though we may not be able to prevent people from being exposed to traumatic events or
from developing PTSD, this should not deter us from viewing PTSD as an important,
modifiable CVD risk factor.51 Unfortunately, despite the high prevalence of trauma and
PTSD and the existence of brief, validated screening tools, PTSD is often not assessed in
medical care settings.52–54 A nationally representative survey of US adults also found that
only 7% of patients with PTSD received treatment within the first year after symptom onset
and the median time between initial symptoms and treatment was 12.1 years.55 Recognition
of damaging downstream consequences, such as increased CVD risk, may help improve
awareness of PTSD and adoption of PTSD screening and treatment programs that can
reduce delays to receiving care.
To date, no study has tested whether PTSD treatment can reduce risk for incident CVD or
has evaluated other specific methods of decreasing CVD risk in patients with PTSD.
Therefore, at present, the most widely offered strategy for offsetting the CVD risk associated
with PTSD due to traumatic events has been increased screening for and treatment of PTSD
with concomitant screening for CVD risk factors to initiate early interventions for CVD risk
factor control. Although improvements in traditional CVD risk factors are likely to be
beneficial, as described above, these factors explain only a modest portion of the CVD risk
associated with PTSD. Therefore, we must develop a better understanding of the
mechanisms linking PTSD and CVD in order to design targeted interventions to reduce
cardiovascular events and mortality in patients with PTSD.
Fortunately, multiple trials have demonstrated that the potential mediators described above
can be improved with behavioral and pharmacologic therapies.29 For example, pro-
inflammatory biomarkers such as interleukin-6 and C-reactive protein decrease in response
to exercise interventions.56,57 Treatment with statins also reduces inflammatory biomarker
levels and adverse CVD outcomes.58 In addition, several studies have successfully targeted
behavioral risk factor reduction to patients in PTSD. For example, integration of tobacco
cessation counseling in mental health care significantly improved abstinence over an 18
month period in patients with PTSD, and both prazosin and cognitive behavioral therapy
have demonstrated efficacy for sleep disturbances in PTSD.59,60 As research continues to
identify which of these mechanisms are most important and therefore promising for targeted
CVD risk reduction, ongoing trials of pharmacologic and behavioral treatments for PTSD
could examine the direct effects of PTSD symptom reduction on these potential
mechanisms.
PTSD due to cardiovascular events
While PTSD is widely considered a disorder of combat veterans and sexual assault
survivors, in the Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition;
DSMIV), 61 life-threatening medical illness is recognized as an event that can elicit PTSD.
In the nearly 20 years since that expansion of the PTSD diagnostic criteria to include life-
threatening illness, a large body of research 62 has documented substantial rates of PTSD
due to cancer,63–71 acute coronary syndromes (ACS),72–78 and stroke.79–84 Because of the
relative homogeneity of the type of traumatic event that induces PTSD symptoms within
ACS and stroke patient populations, the elevated recurrent CVD risk endemic to those
populations, and the existence of a few strong cohort studies of survivors of CVD events, we
have gained substantial knowledge about the prevalence of PTSD due to CVD, its
association with CVD recurrence risk and mortality, and potential mechanisms by which
that risk is carried.
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1. Prevalence of PTSD due to acute coronary syndromes
In a systematic review and meta-analysis of 24 studies (N = 2383), we sought to determine
the prevalence of PTSD after ACS. Our pooled estimate for the prevalence of ACS-induced
PTSD was 12%,72 however, estimates of the prevalence of PTSD varied widely. That
variability may be due to a number of sampling and research design decisions or may reflect
some true demographic, clinical, or geographic variability in the susceptibility of ACS
patients to PTSD.
Positive screen versus diagnosis
In any discussion of the prevalence of a psychiatric disorder, the method for determining
cases will partially dictate the prevalence estimate. In most of the extant studies of ACS-
induced PTSD, researchers have relied on self-report screening instruments. Many of those
instruments have good to excellent agreement with clinical diagnosis, but the level of
agreement depends on the use of an appropriate cutoff score, which may vary depending on
sample characteristics. A few studies have employed clinicians to conduct full clinical
diagnostic interviews for ACS-induced PTSD. In our meta-analysis of the prevalence of
ACS-induced PTSD, we found that the aggregate estimate of the 17 studies in which
patients were assessed solely with screening questionnaires was 16% (95% CI, 13%–20%),
compared with 4% in the 7 studies in which patients were assessed with clinical interviews
(95% CI, 3%–5%). While the discrepancy between these estimates may be important for
patients’ quality of life and psychiatric treatment decisions, studies that have found
increased risk for subsequent ACS and mortality associated with PTSD symptoms have all
relied on screening questionnaires, suggesting that the 16% of ACS patients with elevated
symptoms are at increased risk for adverse outcomes.
Study factors associated with PTSD prevalence
Across the 24 studies that have assessed ACS-induced PTSD, prevalence estimates varied
from 0%–32%. However, the largest of the studies included 394 participants, and all of the
studies were in fairly homogenous samples (in terms of race/ethnicity/socioeconomic status/
culture/nationality), suggesting that no individual estimate is particularly representative of
the population from which it was drawn and certainly not representative of the population of
all ACS survivors. We found that studies comprised of younger participants tended to have
higher rates of ACS-induced PTSD, a phenomenon that is reflected in patient-level PTSD
prediction models across studies of PTSD due to life threatening illness. Younger ACS
survivors may view their ACS event as particularly threatening because it may be among
their first major illnesses, and they have seen fewer of their peers experience such events.
Patient-level factors associated with PTSD risk
Patient-level risk factors for ACS-induced PTSD include intense fear,85 perceived life
threat, lack of control, 86 helplessness, chest pain, 87 and/or dissociation during the ACS
event, acute stress disorder and/or depression symptoms during hospitalization, 88 history of
psychiatric disorder prior to ACS, 88 alexithymia, 89 and neuroticism.90 It is important to
note that most people who experience life threatening events respond with some degree of
fear and psychological distress, but extreme distress during the event defines that event as
traumatic and is a potent predictor of future PTSD. Demographic factors associated with
ACS-induced PTSD in some studies include younger age,91 female sex,88 ethnic minority
status, and low socioeconomic status.91 While these scattered risk factor studies have been
useful, a unified risk stratification strategy is warranted for predicting which patients are
most likely to develop ACS-induced PTSD. It is important to note that objective clinical
severity of the ACS event is not associated with ACS-induced PTSD, either at the study
level or at the patient-level, a fact that tends to reinforce the common belief that personality
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factors, previous psychiatric history, and other individual patient traits fully determine which
patients will develop ACS-induced PTSD. However, recent research suggests that external
factors during ACS treatment can also significantly influence the development of ACS-
induced PTSD symptoms.
Treatment factors and risk for PTSD
The experience of an ACS is probably universally frightening to some degree, but in order
for an individual to develop PTSD, a life threatening event generally must induce feelings of
intense fear, helplessness, and/or horror (though the diagnostic criteria for PTSD may soon
disregard the requirement that patients report these subjective feelings). Since a major
component of the experience of an ACS occurs in emergency departments (ED) and
catheterization labs, we recently tested the hypothesis that more stressful medical
environments increase the likelihood of developing PTSD after an ACS. We recorded the
initial triage time of each of 135 ACS patients, estimated the degree of ED crowding they
experienced, and then assessed their ACS-induced PTSD symptoms 1 month later. We
divided the ED crowding variable into tertiles, and found that for every tertile increase in
ED crowding, participants experienced a 2.5 point increase in PTSD score, after adjustment
for a number of demographic, clinical, and psychiatric covariates.92 It may be the case that
pre-existing person-level factors may exacerbate individual patients’ responses to ED
crowding, but our results suggest an independent effect of ED crowding on the development
of ACS-induced PTSD. Interestingly, while symptoms of depression at the time of the ACS
are patient-level predictors of subsequent development of PTSD, the presence of depression
symptoms during ED treatment does not influence the association of ED crowding to the
development of PTSD symptoms.93
Course of PTSD over time
For some of the same reasons that we are unsure of the true prevalence of ACS-induced
PTSD, the true course of PTSD symptoms is unknown, and is likely influenced by a number
of demographic, clinical, and psychosocial factors. Wikman and colleagues94 found that
12% of 213 participants screened positive for ACS-induced PTSD at 12 months post-ACS,
and that 12.8% of 179 of those participants screened positive for ACS-induced PTSD at 36
months. However, while PTSD symptoms were relatively stable, there were participants
who screened positive at 12 months who did not at 36 months, and vice versa, as 63% of the
variance in 36 month PTSD symptoms were explained by 12 month PTSD symptoms.
Ginzburg and colleagues95 published the longest follow-up of ACS patients with
measurement of ACS-induced PTSD, with multiple measurements of PTSD symptoms over
multiple years. They found that participants generally were able to be categorized into a
large resilient group who experience some psychological distress in the first 7 months after
the ACS but recover, and a much smaller group of about 6% of participants who still had
significant ACS-induced PTSD symptoms 8 years later.
Future directions
A number of studies have now shown that ACS-induced PTSD is relatively common, but a
great deal of variability exists across individual study prevalence estimates. A large national
study would not only give a more precise estimate of the prevalence of ACS-induced PTSD,
but would also offer an opportunity to tease out geographical and socioeconomic variables
from race/ethnicity and other person-level predictors toward a PTSD risk prediction tool
similar to a Framingham or GRACE score, but instead for the prediction of ACS-induced
PTSD. Perhaps more important, though, is the possibility that there are modifiable factors
that occur during the course of ACS care that may influence the development of PTSD
symptoms, such as ED crowding. Future research should further elucidate those factors and
the mechanisms by which they may influence PTSD toward the development of
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organizational interventions to reduce ACS-induced PTSD incidence. In the meantime, we
know that 1 in 8 ACS patients are developing ACS-induced PTSD, but only one small
treatment study exists that was not powered to detect even large effect sizes. This small
study did suggest that ACS-induced PTSD treatment is safe and promising.96 Aside from the
quality of life benefits that would likely attend successful ACS-induced PTSD treatment,
such treatment may also offset secondary ACS recurrence and mortality risk in ACS
patients.
2. Association of ACS-induced PTSD to ACS recurrence/mortality
In the same article in which we estimated the prevalence of ACS-induced PTSD from 24
studies, we used meta-analysis to estimate the effect size of the association between ACS-
induced PTSD and risk of adverse outcome based on estimates provided by the 3 studies that
prospectively assessed this association. The first study to assess the association of ACS-
induced PTSD to cardiac rehospitalization was Shemesh and colleagues’97 study in 73 ACS
patients followed for 1 year post-ACS, but that study did not adjust for potential
confounders of the association including demographics, disease severity, or depression.
Seven years later, two other studies documented an association between ACS-induced PTSD
and ACS recurrence and/or mortality. Edmondson and colleagues73 measured ACS-induced
PTSD symptoms 1 month post-ACS in 247 participants, then followed them for 42 months
to ACS recurrence or mortality. The unadjusted hazard ratio (HR) associated with a positive
screen for PTSD was 2.42 (95% CI, 1.1–5.4), but after adjustment for sociodemographic and
clinical disease severity, the HR for positive ACS-induced PTSD screen was attenuated to
2.04 (95% CI, 0.9–4.9). After further adjustment for depression symptoms during
hospitalization, the HR was further attenuated to 1.36 (95% CI, 0.5–3.5). However, when
the three symptom clusters of PTSD (reexperiencing, avoidance, and hyperarousal) were
considered separately in the fully adjusted model, participants who reported high levels of
reexperiencing symptoms (i.e., intrusive thoughts, nightmares) were at significantly greater
risk for ACS recurrence and mortality, HR= 3.35 (95% CI, 1.3–8.8). Similarly, von Kanel
and colleagues98 found that risk for ACS recurrence increased with each 10 point increase in
ACS-induced PTSD symptoms (measured around 3 months post-ACS), with a HR of 1.42
(95% CI, 1.1–1.9).
By combining the three estimates, we found that a positive screen for ACS-induced PTSD is
associated with an approximate doubling of the risk of adverse medical outcomes, even after
adjusting for depression and other important covariates (adjusted hazard ratio HR, 2.0; 95%
CI, 1.7–2.4). 72 It is important to note that each of these studies used a cutoff on an ACS-
induced PTSD symptom questionnaire rather than a clinical interview to classify PTSD
status, suggesting that the larger of the two prevalence estimates—the estimate based on
self-report screening instruments—is the estimate that is most important in terms of possible
ACS recurrence risk stratification based on PTSD status. As such, if the aggregate
prevalence estimate based on extant studies of ACS-induced PTSD is valid, we expect that
about 16% of ACS patients develop PTSD symptoms severe enough to place them at
increased ACS recurrence or mortality risk.
3. Mechanisms
Many of the mechanisms that have been proposed to explain the association between ACS-
induced PTSD and adverse outcomes are the same as those proposed to explain the
association of PTSD to incident CVD. However, whereas the average length of follow-up
for studies that have shown an association of PTSD to incident CVD is almost 10 years,
ACS-induced PTSD seems to increase risk for recurrent ACS and mortality within a few
months or years. As such, either the mechanisms that are thought to exert long-term
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cumulative effects on the cardiovascular system work more quickly in post-ACS patients, or
the more short-acting mechanisms are the most likely candidates for mediators of the ACS-
induced PTSD to ACS recurrence/mortality association.
Physiological risk factors more pronounced in ACS-induced PTSD
We know that both ACS and PTSD are associated with sympathetic activation and elevated
proinflammatory cytokines, including C-reactive protein 99, tumor necrosis factor, and
interleukin 1 99. It is likely that the additive effects of the inflammation found in patients
with PTSD may adversely affect recurrence risk.100 Recently, Ahmadi and colleagues101
showed that PTSD is associated with mortality more strongly at higher levels of coronary
artery calcium, suggesting that PTSD may exert greater influence on secondary risk than
primary risk.
Behavioral risk factors
Among the behavioral risk factors mentioned above, the two most likely candidates for
mechanisms of the ACS-induced PTSD- secondary risk association are medication
nonadherence and sleep disruption. While the small Shemesh97 study discussed above could
not adjust for important covariates in the PTSD to rehospitalization association, it did show
that participants who screened positive for ACS-induced PTSD were more likely to show
evidence of nonadherence to aspirin in the months after their index ACS. Medication
nonadherence may exacerbate many of the physiological mechanisms that have been
proposed. Sleep difficulties are a common feature of PTSD,41 and are also a common
complaint after ACS.102,103 While sleep difficulties have been shown to be associated with
CVD events,44 no study has yet tested poor sleep as a mediator of the association of ACS-
induced PTSD and adverse CVD outcomes.
Prevalence of PTSD due to stroke
While most studies of the relationship between PTSD and cardiovascular disease have
focused on the potential for PTSD due to ACS, a few studies have assessed stroke-induced
PTSD. Across the eight extant studies, prevalence estimates vary widely from 3% to
37%.79,81,83,84,104–106 Moreover, most of those studies relied on small samples assessed at
various lengths of time after the index stroke. Further, most published studies to date were
conducted in majority white populations without significant racial or ethnic diversity,
although risk for PTSD is greater in black survivors of some types of trauma.107,108 Our
recent study, the largest on this topic to date, found that 18% of 535 survivors of mild to
moderate stroke reported clinically significant PTSD symptoms a mean ± SD of 1.9 ± 1.5
years later.80 Strikingly, in that study, we found that participants with elevated stroke-
induced PTSD symptoms were 2.7 times more likely than those without PTSD symptoms to
report medication nonadherence.80 However, the participants in that study were primarily
from racial and ethnic minority groups with very low socioeconomic status living in New
York City,109 so the generalizability of that result to the broader population of stroke
survivors in the United States is unclear.
Conclusions
Research conducted in the past decade has now accumulated such that we can confidently
conclude that an association exists between PTSD and incident CVD, and likely exists
between PTSD and recurrent CVD, and that the association is independent of other known
risk factors. However, we are not able to point to a single mechanism that can explain that
association. That inability likely exists for two reasons: the studies that could pinpoint that
mechanism have not been conducted, and the association is carried by multiple mediators
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whose relative effects are contingent upon individual patient factors. Future research should
focus on (1) methods for decreasing PTSD, particularly where medical settings can be
modified to decrease PTSD due to ACS, stroke, and other life-threatening medical illnesses,
(2) identifying modifiable mechanisms of the association of PTSD and CVD, particularly
non-traditional risk factors, and (3) determining whether PTSD treatment can offset CVD
risk.
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